$ABBV (AbbVie Inc.)

$ABBV {{ '2016-04-28T22:40:16+0000' | timeago}} • Webcast

$ABBV said Stemcentrx has a broad development program for Rova-T currently underway. The confirmatory third-line trial which is called Trinity began in January and is expected to complete enrollment by the end of 2016 with commercialization expected in 2018. Stemcentrx is also moving into front-line, small cell lung cancer with Rova-T.

$ABBV {{ '2017-12-21T13:23:43+0000' | timeago}} • Announcement

$ABBV announced positive top-line results from the Phase 3 SELECT-MONOTHERAPY clinical trial. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.

$ABBV {{ '2017-12-04T15:31:15+0000' | timeago}} • Announcement

$ABBV announced that Risankizumab met all co-primary and ranked secondary endpoints in Phase 3 study. Risankizumab is used in the treatment of patients with moderate to severe plaque psoriasis.

$ENTA {{ '2017-11-20T21:52:37+0000' | timeago}} • Announcement

Biotech company $ENTA swung to 4Q17 profit on higher revenue, driven by milestone payments totaling $65MM received following $ABBV's U.S. approval of MAVYRET and EU approval of MAVIRET. Net income was $36.5MM or $1.86 per share in the quarter compared to a net loss of $1.8MM, or $0.09 loss per share a year earlier. Revenue jumped to $75.9MM.

$ABBV {{ '2017-10-27T19:44:43+0000' | timeago}} • Webcast

As $ABBV posted 3Q17 results, it now sees full-year gross margin as a percentage of sales at 80.5% and operating margin at 42.5%. AbbVie also expects full-year net interest expense of approximately $1Bil with an adjusted tax rate of about 19%.

$ABBV {{ '2017-10-27T16:20:17+0000' | timeago}} • Infographic

$ABBV AbbVie, Inc. Earnings AlphaGraphic: Q3 2017 highlights

$ABBV {{ '2017-10-27T12:14:02+0000' | timeago}} • Announcement

$ABBV, as it posted 3Q17 results, declared an 11% hike in the quarterly cash dividend to $0.71 per share, beginning with the dividend payable on Feb. 15, 2018 to shareholders of record as of Jan. 12, 2018.

$ABBV {{ '2017-10-27T12:12:54+0000' | timeago}} • Announcement

As $ABBV posted 3Q17 results, it updated its GAAP diluted EPS guidance for FY17 to $4.27-4.29. AbbVie now expects to deliver adjusted diluted EPS for the full year of $5.53-5.55. The drug giant now sees global HUMIRA sales to approach $21Bil in 2020.

$ABBV {{ '2017-10-27T12:11:23+0000' | timeago}} • Announcement

With worldwide net revenues jumping 8.8% to about $7.0Bil in 3Q17, $ABBV saw net earnings inch up 2% to $1.6Bil or $1.01 per diluted share. Global HUMIRA sales saw a 15% hike while global IMBRUVICA net revenues surged 37% in the quarter.

$ABBV {{ '2017-10-18T16:05:30+0000' | timeago}} • Announcement

$ABBV and Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting biologic therapies, announced that they have entered an immuno-oncology research collaboration.

$ABBV {{ '2017-09-27T12:14:25+0000' | timeago}} • Announcement

$ABBV announced that the Japanese Ministry of Health, Labor and Welfare has approved MAVIRET, a once-daily, treatment for adults with chronic hepatitis C virus infection. The treatment was also recently granted marketing authorization by the European Commission and approved by the US FDA.

$ABBV {{ '2017-09-22T11:48:04+0000' | timeago}} • Announcement

$ABBV and $BMY announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).

$ABBV {{ '2017-09-08T16:14:15+0000' | timeago}} • Announcement

$ABBV's BoD declared a quarterly cash dividend of $0.64 per share. The dividend is payable on Nov. 15, 2017 to stockholders of record on Oct. 13, 2017. Since the company's inception in 2013, $ABBV has increased its dividend by 60%.

$ABBV {{ '2017-09-06T15:45:07+0000' | timeago}} • Announcement

$ABBV, in cooperation with $NBIX, has submitted a New Drug Application to the FDA for elagolix, an investigational, orally administered gonadotropin-releasing hormone antagonist, being evaluated for the management of endometriosis with associated pain. The pain includes daily menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse.

$ABBV {{ '2017-08-04T18:18:09+0000' | timeago}} • Announcement

The FDA approved $ABBV’s Mavyret to treat adults with chronic hepatitis C virus across all major genotypes (GT1-6). It is an 8-week treatment for patients without cirrhosis and who are new to treatment. Up to 95% of HCV patients in the U.S. may be eligible for the new cure, including those with compensated cirrhosis and limited treatment options.

$ABBV {{ '2017-08-03T13:59:03+0000' | timeago}} • Announcement

$ABBV got the FDA nod for Imbruvica (Ibrutinib) used for treating adult patients with chronic graft-versus-host-disease after failure of one or more treatment. This is the first drug approved to treat the disease, a serious fallout of stem cell or bone marrow transplant. It was co-developed by Pharmacyclics, an AbbVie company, and Janssen Biotech.

$ENTA {{ '2017-07-28T21:01:27+0000' | timeago}} • Announcement

$ENTA said the European Commission (EC) has granted $ABBV marketing authorization for Maviret (glecaprevir/pibrentasvir) for treatment of chronic hepatitis C virus (HCV) infection across all major genotypes. $ENTA expects to receive a $25MM milestone payment from $ABBV.

$ABBV {{ '2017-07-28T15:50:59+0000' | timeago}} • Infographic

$ABBV AbbVie, Inc. Earnings AlphaGraphics: Q2 2017 highlights

$ABBV {{ '2017-07-28T12:13:15+0000' | timeago}} • Announcement

Global HUMIRA sales for $ABBV rose 13.7% in 2Q17, while Global IMBRUVICA net revenues jumped 42.6%. The gross margin ratio in the second quarter was 78.0%, with adjusted gross margin ratio at 82.3%.

$ABBV {{ '2017-07-28T12:04:31+0000' | timeago}} • Announcement

While posting 2Q17 results, $ABBV confirmed its GAAP diluted EPS guidance for FY17 of $4.55-4.65. AbbVie expects to deliver adjusted diluted EPS of $5.44 to $5.54, representing growth of 13.% at the mid-point.

$ABBV {{ '2017-07-28T12:02:43+0000' | timeago}} • Announcement

With the biopharma giant's net revenues up 7.6% to $6.9Bil in 2Q17, $ABBV's net earnings soared 19% to $1.9Bil or $1.19 per share.  Adjusted diluted EPS was $1.42, up 12.7% in the quarter.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
NKTR (Nektar Therapeutics)
Tuesday, November 7 2017 - 10:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
IRWD (Ironwood Pharmaceuticals, Inc.)
Thursday, November 2 2017 - 12:30pm
BDX (Becton, Dickinson and Company)
Thursday, November 2 2017 - 12:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
ACOR (Acorda Therapeutics, Inc.)
Tuesday, October 31 2017 - 12:30pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
AMGN (Amgen Inc)
Wednesday, October 25 2017 - 9:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, October 25 2017 - 8:30pm
BIIB (Biogen Inc.)
Tuesday, October 24 2017 - 12:30pm
ABT (Abbott Laboratories)
Wednesday, October 18 2017 - 1:00pm

AlphaGraphics you may like